Purpose Genetic variants and traits in metabolic signaling pathways may interact with obesity, physical activity, and exogenous estrogen (E), influencing postmenopausal breast cancer risk, but these inter-related pathways are incompletely understood. Methods We used 75 single-nucleotide polymorphisms (SNPs) in genes related to insulin-like growth factor-I (IGF-I)/insulin resistance (IR) traits and signaling pathways, and data from 1003 postmenopausal women in Women's Health Initiative Observation ancillary studies. Stratifying via obesity and lifestyle modifiers, we assessed the role of IGF-I/ IR traits (fasting IGF-I, IGF-binding protein 3, insulin, glucose, and homeostatic model assessment-insulin resistance) in breast cancer risk as a mediator or influencing factor. Results Seven SNPs in IGF-I and INS genes were associated with breast cancer risk. These associations differed between non-obese/active and obese/inactive women and between exogenous E non-users and users. The mediation effects of IGF-I/IR traits on the relationship between these SNPs and cancer differed between strata, but only roughly 35% of the cancer risk due to the SNPs was mediated by traits. Similarly, carriers of 20 SNPs in PIK3R1, AKT1/2, and MAPK1 genes (signaling pathways-genetic variants) had different associations with breast cancer between strata, and the proportion of the SNP-cancer relationship explained by traits varied 45-50% between the strata. Conclusions Our findings suggest that IGF-I/IR genetic variants interact with obesity and lifestyle factors, altering cancer risk partially through pathways other than IGF-I/IR traits. Unraveling gene-phenotype-lifestyle interactions will provide data on potential genetic targets in clinical trials for cancer prevention and intervention strategies to reduce breast cancer risk.
Introduction
Breast cancer is the most commonly occurring cancer in women and the second most common cause of cancer-related deaths in the United States [1] . The insulin-like growth factor-I (IGF-I)/insulin resistance (IR) axis demonstrates strong associations with breast cancer [2] [3] [4] [5] . Total and/or free bioavailable IGF-I proteins are associated with higher breast cancer risk and worse cancer survival in premenopausal and postmenopausal women [6] [7] [8] . In postmenopausal women, high insulin levels have been associated with a twofold increase in breast cancer risk [9, 10] , and homeostatic model assessment-insulin resistance (HOMA-IR), reflecting high blood levels of insulin and glucose, is positively associated with breast cancer in this population [11] .
High IGF-I levels and IR (characterized by hyperinsulinemia and hyperglycemia) activate the IGF/insulin receptors, which are overexpressed in breast cancer. This overexpression results in the enhanced anabolic state necessary for cell proliferation, differentiation, and anti-apoptosis via deregulating or overactivating multiple downstream signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) pathways [12] [13] [14] . Thus, high IGF-I levels and IR contribute to overexpression of relevant receptors and multiple abnormal cellular signaling cascades, and therefore may be associated with carcinogenesis.
Considering the relationships between IGF-I/IR traits and cancer risk, the IGF-I/IR-related genetic variants (e.g., singlenucleotide polymorphisms [SNPs] ) that may influence high IGF-I, insulin, glucose, and HOMA-IR levels are possibly associated with increased risk of breast cancer. However, epidemiologic studies of these relationships among postmenopausal women are limited and have presented inconsistent findings [15] [16] [17] [18] [19] [20] [21] [22] , mainly due to different sets of covariates; lack of consideration of adjustment of relevant phenotypes and of interactions with lifestyle effect modifiers; and different races/ ethnicities. In addition, the genetic alterations of IGF-I/IR signaling pathways lead to altered gene expression and protein function and are found in more than 70% of breast cancers [23] . Thus, the genetic variants that are related to IGF-I/IR signaling pathways are plausibly associated with increased risk of breast cancer, although population-based studies to examine these relationships have been limited [12, [24] [25] [26] [27] .
Breast cancer risk, particularly in postmenopausal women, is elevated among obese women [2, [28] [29] [30] , and obesity status and obesity-related lifestyle factors such as inactivity are accompanied by elevated circulating IGF-I levels and IR traits [2, 5, 19, 20, 28, 29, [31] [32] [33] . Further, previous in vitro studies have revealed obesity-IGF-I/IR-related gene signaturebreast cancer pathways, suggesting that genetic variants related to IGF-I/IR traits and their signaling pathways interact with obesity and jointly influence cancer susceptibility [3, 34] .
Additionally, in postmenopausal women, endogenous estrogen (E) interacts with IGF-I/IR traits and their signaling pathways as well as their target genes in a synergistic cross-talk mechanism, resulting in the enhanced anabolic state necessary for tumor growth and development [2, 4, 28, 34, 35] . Likewise, oral exogenous E in this population has been postulated to interact with circulating levels of IGF-I/IR and their transduction pathways to affect cancer risk. However, unopposed E (i.e., E alone) has a different effect than opposed E (i.e., E ? progestin [P]) has on IGF-I production. Because of the first-pass effect induced by oral E, resulting in suppressing hepatic production of IGF-I, E-only users have lower IGF-I levels, followed by increased IR [36, 37] and lower risk of breast cancer than non-users [38] [39] [40] . Owing to non-progesterone-like effects, E?P users (compared with E-only users) have different IGF-I levels, IR traits, and breast cancer risk [40] [41] [42] [43] , although the mechanisms are unclear.
In this case-cohort study among postmenopausal women, we evaluated the effect of IGF-I/IR traits (circulating levels of IGF-I, IGFBP3, insulin, glucose, and HOMA-IR) on cancer in two different roles: mediator (in relation to IGF-I/IR trait-related genetic variants) and influencing factor (in relation to IGF-I/IR signaling pathway-related genetic variants). We first focused on the mediation effects relating the genetic variants of IGF-I/IR traits (exposure) and breast cancer (outcome) and on the role of IGF-I/IR traits (mediator) in this association (Fig. 1) . We first evaluated the magnitude of the total effect of the genetic variants of IGF-I/IR traits on breast cancer (i.e., the overall genetic effect, without considering the effect of IGF-I/IR traits). We then evaluated how this total effect is partitioned into indirect (through pathways mediated by IGF-I/IR traits) and direct effects (through pathways of other than IGF-I/IR traits). This approach allowed us to test the hypothesis that the genetic variants of IGF-I/ IR traits are associated with increased risk of breast cancer and that the relationships depend on IGF-I/IR traits. Because IGF-I/IR traits are not mediators in the relationship between IGF-I/IR signaling pathway-relevant genetic variants and breast cancer, we examined the effect of IGF-I/IR traits as an influencing factor (Fig. 2) .
Given that obesity status, physical activity (PA), and exogenous E influence both IGF-I/IR and their genetic factors and, through this complicated mechanism, are associated with breast cancer, we evaluated how the pathway of IGF-I/IR's genetic variants, IGF-I/IR traits, and breast cancer is influenced by obesity, PA, and exogenous E. Unraveling these complicated gene-phenotype-lifestyle interactions will provide insights into the role of the IGF-I/ IR axis in the development of breast cancer.
Materials and methods

Study population
This study included 1003 postmenopausal women enrolled in ancillary studies of the Women's Health Initiative Observation Study (WHI-OS) between October 1, 1993 and December 31, 1998 . Details of the WHI study's design and rationale have been described elsewhere [44] . Women were eligible for the WHI study if they were 50-79 years old, postmenopausal, planned to live in an area near the clinical centers for at least 3 years after study enrollment, and were able to provide written consent. The ancillary studies were designed for a nested case-cohort study within the WHI-OS. In this study design, non-cases were randomly selected from the parent cohort, forming a subcohort which was C X (SNPs in IGF-I/IR traits genes) Y (Cancer risk) Total effect
• C is a total effect (overall genetic effect, without considering the effect of IGF-I/IR traits), expressed via HR.
• C' is a direct effect (cancer risk associated with IGF-I/IR traits-relevant genetic variants through pathways other than IGF-I/IR traits), expressed via HR after accounting for mediator.
• a*b (≈C-C') is an indirect effect (cancer risk associated with IGF-I/IR traits-relevant genetic representative of the underlying population. For the purposes of our study, we initially included 1491 women who reported their race or ethnicity as non-Hispanic white and were eligible for the breast case-cohort study ( Figure S1 ). Of those 1491 women, we finally included a total of 1003 women (breast cancer cases = 539, controls = 464). As of February 29, 2004 , the ancillary studies completed the selection of women with a mean follow-up of 77 months [10] . This study was approved by the institutional review boards of each participating clinical center of the WHI and the University of California, Los Angeles.
Data collection and cancer outcome variables
Standardized written protocols had been used to ensure uniform data collection. At baseline, self-administered questionnaires were completed by participants on demographic (age, education, family income, and family histories of DM or breast cancer) and lifestyle (PA, smoking status, and alcohol intake) factors and their medical (heart failure and hypercholesterolemia) and reproductive histories (oral contraceptive and exogenous E use [E-only and E?P users], history of hysterectomy or oophorectomy, ages at menarche and menopause, and history of pregnancy). Anthropometric measurements (height, weight, and waist and hip circumferences) were measured at baseline by trained staff. These variables were originally selected for this study on the basis of a literature review for their associations with IGF-I/IR and breast cancer; after multicollinearity testing and univariate and stepwise regression analyses, they were finally determined to be analyzed. Cancer outcomes were determined using a centralized review of medical charts, and cancer cases were coded according to the National Cancer Institute's Surveillance, Epidemiology, and End Results guidelines [45] . The outcome variables were breast cancer and the time to development of breast cancer. The time from enrollment to breast cancer development, censoring, or study end-point was recorded as the number of days and then converted into years.
Genotyping
Ten genes (Tables S1.1-6) were selected based on the biological significance of their gene products, or whether epidemiologic and/or experimental data support an association between the gene and the levels of IGF and insulin or between the gene and risk of cancer [12, [15] [16] [17] [18] [19] [20] [21] [22] [24] [25] [26] [27] . For each gene, HTSNP2 (http://www-gene.cimr.cam.ac.uk/ clayton/software/stata) searched all possible subsets of SNPs that best captured the full haplotype information. Specifically, the selected SNPs had a minimum allelic association of 0.8 with the unselected SNPs within an LD block. A total of 75 SNPs from 10 genes were identified.
The MassARRAY system (Sequenom, Inc., San Diego, CA), based on mass spectrometry, was used for genotyping. Quality assurance was conducted according to a standardized protocol, with a missing call rate of \1%, the number of discordant calls \3%, and Hardy-Weinberg Equilibrium of p C 10 -4 .
Laboratory methods
Fasting blood samples had been collected from each participant at baseline by trained phlebotomists. A total and direct effect size of IGF-I/IR trait-related SNP (exposure) on breast cancer (outcome) was produced from the HR for IGF-I/IR trait-related SNP on cancer in the Cox model that included all covariates, without (total) and with (direct) IGF-I/IR traits (mediator). The mediation effect size was produced via a traditional statistical method [47, 48] : the percentage change in the HRs by comparing a model that includes all covariates with a model that includes all covariates and the mediator. In addition, the effect of IGF-I/IR traits on risk for breast cancer that is related to IGF-I/IR signaling pathway-relevant genetic variants was estimated using the same algorithm as that of mediator, but it was interpreted as an influential factor ( Figure 2 ). To evaluate the role of obesity, PA, and exogenous E as effect modifiers on the IGF-I/IR genetic factor-IGF-I/IR trait-cancer relationship, we used a stratification approach. A two-tailed p value \0.05 was considered statistically significant. The R statistical package (v 2.15.1) was used.
Results
Participants' baseline characteristics and allele frequencies of 75 SNPs by obese status, level of PA, and exogenous E use are presented in Supplementary Tables S1.1-6 and S3.1-6. The participants had been followed up through February 29, 2004 , resulting in 539 breast cancer cases (52% of non-obese and 56% of obese women).
Breast cancer risk associated with IGF-I/IR traitrelated SNPs mediated through IGF-I/IR traits, stratified by obesity status (BMI, waist, and w/h), level of PA, and exogenous E use
We partitioned the total effect of IGF-I/IR trait-related SNPs on breast cancer risk into direct (not via IGF-I/IR traits) and indirect (via IGF-I/IR traits) effects. Each SNP in this analysis was mediated via fasting levels of total and free IGF-I, IGFBP3, glucose, insulin, and HOMA-IR. For each SNP with mediators, the IGF-I/IR trait-SNP-cancer association was evaluated, stratified by obesity status (BMI \30 vs. C30; waist B88 cm vs. [88 cm; and w/h B0.85 vs. [0.85), level of PA (MET C10 vs. \10) ( Table 1) , and by exogenous E use (non-users vs. E-only or E?P users) ( Table 2) .
Among 19 IGF-I/IR trait-related SNPs, 7 SNPs in IGF-I and INS genes were significantly associated with breast cancer risk (Tables 1, 2) . Overall, the SNP-cancer associations differed between non-obese/active and obese/inactive women, and between exogenous E non-users and users. In both strata, the SNP-cancer risk effect was stronger in each SNP for a direct effect than an indirect (mediation) effect regardless of the mediator, but the mediation effects differed between non-obese/active and obese/inactive women and between exogenous E non-users and users.
Carriers of the IGFI rs10860865 T and the IGFI rs978458 T alleles had increased breast cancer risk among the non-obese (BMI \30, waist B88 cm) and inactive groups. The mediation (IGFBP3 level) effects on these SNP-cancer associations in the non-obese groups were minimal, compared with those (roughly 35%) in the obese groups. The mediation (insulin and HOMA-IR levels) effect in inactive women was also minimal, whereas in active women the mediation effect was moderate, roughly 45% (Table 1) .
Carriers of the IGFI rs5742671 A and the IGFI rs1520220 G alleles had associations similar to those found in the inactive group of carriers of the IGFI rs10860865 and the IGFI rs978458, showing that they had an association with increased breast cancer risk in inactive women. Similarly, the mediation effects in those carriers on the SNP-cancer association were minimal in inactive women and smaller than those in the active women (roughly 40%).
In contrast, carriers of the INS rs689 T allele had decreased breast cancer risk in non-obese women (waist B88 cm), and the mediation effects of insulin and HOMA-IR in this group were negligible. Notably, these carriers among exogenous E non-users ( Table 2) had an increased risk of breast cancer, with roughly 60% of cancer risk attributable to this variant that was mediated via HOMA-IR levels.
Breast cancer risk associated with IGF-I/IR signaling pathway-related SNPs and IGF-I/IR traits, stratified by obesity status (BMI, waist, and w/h), level of PA, and exogenous E use Because IGF-I/IR traits are not mediators of the relationship between SNPs in IGF-I/IR signaling pathway genes (in this study, the IRS1, TCF7L2, PIK3R1, AKT1/2, and MAPK1/3 genes) and breast cancer, instead of the mediation effect of the traits, we estimated a proportion explained by the traits as an influencing factor for the SNPcancer relationship (Fig. 2) . For each SNP, the proportion was estimated using the traits, stratified by obesity status, level of PA (Table 3) , and exogenous E use (Table 4) . Of the 56 IGF-I/IR signaling pathway-related SNPs, 20 SNPs were significantly associated with breast cancer risk. Overall, the association between the SNP and cancer differed by obesity, PA, and exogenous E use. Further, the proportion of the SNP-cancer association explained by traits differed between those strata.
In relation to the SNPs in the PIK3R1 gene, carriers of 4 SNPs (rs12657050 T, rs171649 A, rs831123 G, and rs7707370 C alleles) had increased risk of breast cancer in obese women (BMI C30 kg/m 2 ), with roughly 40% of breast cancer risk owing to each genetic variant that was explained by traits (Table 3 ). In addition, carriers of another 4 SNPs in the PIK3R1 gene (rs706711 A, rs1664577 G, rs3730089 A, and rs251404 T alleles) also had increased risk of breast cancer in obese women with w/h [0.85. About 50% of breast cancer risk associated with each genetic variant was dependent on traits (Table 3) . Interestingly, carriers of the PIK3R1 rs831123 G allele, in whom increased cancer risk was found in women with BMI C30, had an association with increased breast cancer risk in non-users of exogenous E (Table 4) ; however, the effects of total and free IGF-I on the SNP-cancer 
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A/G Participants with available IGFBP3 levels, stratified by physical activity (PA) level as active (MET C10; n = 545) or inactive (MET \10; n = 457); participants with available total IGF-I levels, stratified by PA level as active (n = 544) or inactive (n = 458); participants with available glucose levels, stratified by PA level as active (n = 542) or inactive (n = 455); participants with available insulin levels, stratified by PA level as active (n = 534) or inactive (n = 448); participants with available HOMA-IR levels, stratified by PA level as active (n = 534) or inactive (n = 448) Table 3 continued Table 3 continued Multivariate regression was adjusted by covariates (age, education, family income, family histories of diabetes mellitus or breast cancer, heart failure ever, high cholesterol requiring pills ever, smoking status, alcohol intake, and reproductive history [oral contraceptive and history of hysterectomy or oophorectomy, ages at menarche and menopause, and history of pregnancy]); effect modifier variables (physical activity, BMI, and exogenous estrogen use), when not evaluated as effect modifier variables, were adjusted as a covariate; when stratified via waist circumference or w/h ratio, BMI was not adjusted c Proportional change was estimated via difference in the HRs without (total effect) and with (direct effect) accounting for hormone NA due to either C 50% difference between small effect sizes or C100% difference between two effect sizes Participants with available IGFBP3 levels, stratified by exogenous E use as non-users (n = 340) or E ? P users (n = 284); participants with available total IGF-I levels, stratified by exogenous E use as non-users (n = 341) or E ? P users (n = 284); participants with available free IGF-I levels, stratified by exogenous E use as non-users (n = 329) or E ? P users (n = 266); participants with available insulin levels, stratified by exogenous E use as non-users (n = 337) or E ? P users (n = 281) relationship in this group were minimal. On the contrary, carriers of the PIK3R1 rs16897558 C and the PIK3R1 rs34306 A alleles had an association with increased breast cancer risk in E?P users, with roughly 35% of the SNPcancer association explained by traits (Table 4) . A few SNPs in the AKT1 gene were significantly associated with breast cancer (Tables 3, 4) . Carriers of the AKT1 rs2494744 T allele in non-obese women (BMI \30 and waist B88 cm) had increased risk of breast cancer, with minimal effects of insulin and HOMA-IR levels in those women (Table 3) . Further, carriers of the AKT1 rs2494740 T allele had decreased risk for breast cancer in viscerally obese (waist [88 cm) and inactive women, with minimal effects of the traits on the SNP-cancer association. Additionally, carriers of the AKT1 rs4332845 A allele had an association with decreased risk of breast cancer in nonusers of exogenous E; no effect of free IGF-I level on the SNP-cancer relationship was found in this group (Table 4) .
Five SNPs in the MAPK1 gene were associated with breast cancer risk (Table 3) . While carriers of rs2266966 G, rs2283791 C, and rs9610505 A alleles had an association with decreased breast cancer risk in obese women with w/h [0.85, carriers of rs2298432 T allele had decreased cancer risk in non-obese women with w/h B0.85. Further, the former three carrier groups had a modest effect (30%) of IGFBP3 level on the SNP-cancer relationship, compared with the latter carrier group which had no trait effect.
Discussion
Population-based studies evaluating the association between the genetic variants of IGF-I/IR traits/signaling pathways and breast cancer are relatively few; information on the functionality of those SNPs associated with breast cancer is thus limited. To our knowledge, this is the first study to evaluate in postmenopausal women the association between these genetic variants and breast cancer by partitioning the genetic variant-cancer association into the pathway through IGF-I/IR traits and pathways through other than the traits. Additionally, we assessed the role of obesity with different adiposity measures (overall vs. visceral obesity), PA, and exogenous E use as the effect modifiers.
Among the 75 IGF-I/IR-related SNPs we evaluated, 7 (of the 19 related to IGF-I/IR traits) in IGF-I and INS genes and 20 (of the 56 related to IGF-I/IR signaling pathways) in PIK3R1, AKT1/2, and MAPK1 genes were associated with breast cancer risk. These SNPs' associations with cancer risk differed between non-obese/active and obese/inactive carriers and between exogenous E non-users and users, indicating that the IGF-I/IR-related SNPs' interactions with obesity, PA, and exogenous E use influence cancer risk.
For seven SNPs in IGF-I and INS genes, the mediation effects of IGF-I/IR traits differed between the strata, but the direct effects on cancer risk in both groups accounted for a majority of the total effect: only roughly 35% of the cancer risk associated with those SNPs was mediated via IGF-I/IR traits. This suggests that the traits are not the main mediators through which IGF-I/insulin-related SNPs are associated with increased breast cancer risk; thus, further study is warranted.
In particular, carriers of genetic variants in the IGFI rs5742671 and the IGFI rs1520220 had increased breast cancer risk. The IGFI variants are related to glucose metabolism and are highly expressed in the liver, contributing to hepatic IR [49] . IGFI encodes IGF-I, which is well known to increase cancer risk [50, 51] . Previous studies of these genetic variants in relation to breast cancer are limited and showed inconsistent findings. For example, previous studies revealed no significant relationship of cancer risk and prognosis with the rs5742671 [52] and rs1520220 [5] variants; the rs1520220 variant had significant association with breast cancer risk [17] and breast tissue density [53] . In our study, these genetic variants' carriers had an association with breast cancer, but only among the inactive women, suggesting that obesity and the related lifestyle factors play a role in modulating the effect of these variants on carcinogenesis. Interestingly, the mediation effect of IGF-I/IR traits on the SNP-cancer risk association was negligible in this group, indicating that different pathways exist through which obesity and relevant lifestyles interact with these genetic variants and cancer.
The PI3K/Akt pathway leads to metabolic activity, including glucose uptake and decreased apoptosis, and the MAPK pathway leads to mitogenic activity [54] ; both are main signaling cascades in controlling cellular process promoting carcinogenesis [55, 56] . PIK3R1, AKT1/2, and MAPK1 genes are the key components of these pathways [26, 55, [57] [58] [59] , but the studies of their genetic variants in relation to cancer have been limited [12, [24] [25] [26] [27] .
A previous study [26] showed an interaction between MAPK1 genetic variants and obesity and related lifestyle factors on breast cancer. Consistent with the results of that study, we found that carriers of the genetic variant in MAPK1 rs2298432 had decreased breast cancer risk only in non-viscerally obese women, indicating that IGF/IR axis cellular pathway-related carcinogenesis in this variant intermingles with visceral adiposity. In addition, the carriers of several variants in PIK3R1 and AKT1 genes, when stratified by E?P use status, had decreased or increased cancer risk in non-users and increased risk in E?P users. This suggests that estrogen's cross-talk with target genes downstream of signaling pathways affects cancer risk [2, 4, 28, 34, 35] and that the extent of this influence may be SNP specific and dependent on the type of estrogen usage [36] [37] [38] [39] [40] [41] [42] [43] , but the mechanism is unclear.
We did not conduct any subtype analyses of breast cancer cases due to insufficient statistical power. Also, because we conducted analyses to generate new hypotheses, we did not include any multiple testing adjustments in our analyses. We acknowledge that with many analyses, we might have a few false-positive results. Our findings from the mediation approach and proportion explained by traits of the SNPcancer risk association should be interpreted statistically. Finally, because our study was conducted using data from only non-Hispanic white postmenopausal women, the generalizability of our results to other populations is limited. Despite these possible limitations, however, the potential impact of our findings clearly warrants further study.
In conclusion, our findings suggest that in postmenopausal women the IGF-I/IR axis has a potential role in the risk for breast cancer. Obesity, PA, and exogenous E modulate the IGF-I/IR genetic variant-cancer risk association through pathways other than IGF-I/IR traits. Further studies are needed to explore these complex mechanisms. Our results provide insight into gene-lifestyle interactions and suggest data on potential genetic targets for use in clinical trials for cancer prevention and intervention strategies to reduce breast cancer risk in postmenopausal women.
